Annual report pursuant to Section 13 and 15(d)

NOTE PAYABLE (Details Textual)

NOTE PAYABLE (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
Mar. 03, 2017
Feb. 24, 2017
Sep. 28, 2016
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2013
Note Payable [Line Items]            
Interest Expense, Debt       $ 22,100 $ 8,300  
Debt instrument, unamortized discount       0 977,882  
Repayments of Notes Payable       1,000,000 0  
Registered Direct Offering 2017            
Note Payable [Line Items]            
Stock Issued During Period, Value, New Issues   $ 6,100,000        
Repayments of Notes Payable         $ 50,000,000  
Note Payable [Line Items]            
Notes Payable       944,707    
2014 Warrant            
Note Payable [Line Items]            
Notes Payable       55,293    
Massachusetts Life Sciences Center            
Note Payable [Line Items]            
Subordinated Debt       $ 1,000,000   $ 1,000,000
Debt Instrument, Payment Terms     (i) interest on the MLSC Loan decreased from 10% per annum to 7% per annum beginning October 3, 2016; and (ii) the MLSC Loan became due and payable on the earlier of October 3, 2017 (the Maturity Date), the occurrence of a Corporate Event (which was defined as the occurrence of either a Qualified Sale or Qualified Financing), or the occurrence of a Default (as defined in the promissory note issued in connection with the MLSC Loan Agreement). In addition, under the terms of the Amendment, (a) beginning October 3, 2016, the Company began amortizing the principal and accrued interest under the MLSC Loan by making the first of 13 monthly payments of approximately $106,022, with the last payment scheduled to occur on the Maturity Date; and (b) the term Qualified Financing was defined to mean one or more financing transactions in which we receive, in a single transaction or series of transactions, cumulative net proceeds of not less than five million dollars ($5,000,000) at any time after October 3, 2016. The loan originally bore interest at a rate of 10% per annum, and was originally scheduled to become fully due and payable on the earlier of (i) September 30, 2018, (ii) the occurrence of an event of default under the MLSC Loan Agreement, or (iii) the completion of a sale of substantially all of our assets, a change-of-control transaction (a Qualified Sale) or one or more financing transactions in which we receive from third parties other than our then existing shareholders net proceeds of $5,000,000 or more in a 12-month period    
Warrants Issued To Purchase Of Common Stock           145,985
Class of Warrant or Right, Exercise Price of Warrants or Rights           $ 0.27
Debt Instrument, Increase, Accrued Interest     $ 232,000      
Debt Instrument, Interest Rate, Stated Percentage     7.00%      
Repayments of Notes Payable $ 830,000 830,000        
Debt Instrument Reduction In Interest Expenses   $ 250,000